Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 16/20 | 0.88 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1722930 | 0.94 | BDKRB1 (1.00) | BDKRB1CHRM4 | |
| SCHEMBL6046044 | 0.91 | BDKRB1 (0.86) | BDKRB1CHRM4 | |
| SCHEMBL6046017 | 0.91 | BDKRB1 (0.73) | BDKRB1CHRM4 | |
| SCHEMBL6046018 | 0.91 | BDKRB1 (1.00) | BDKRB1CHRM4F10 | |
| SCHEMBL4704946 | 0.88 | BDKRB1 (0.70) | BDKRB1CHRM4F10 | |
| SCHEMBL6046189 | 0.88 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL6046155 | 0.88 | BDKRB1 (0.82) | BDKRB1CHRM4 | |
| SCHEMBL14085030 | 0.88 | BDKRB1 (0.83) | BDKRB1CHRM4 | |
| SCHEMBL6047131 | 0.87 | BDKRB1 (1.00) | BDKRB1CHRM4 | |
| SCHEMBL5820999 | 0.86 | BDKRB1 (0.80) | BDKRB1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | claimed |
| US-7417152-B2 | 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417152-B2 | 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, CNR1 | BDKRB1 1/4885CHRM4 1131/4885F10 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.